Die Daten über das Medikament Eisai-Biogen Alzheimer bestätigen Vorteile: FDA.

Published Date: 10 Jun 2023

Staff from the US Food and Drug Administration claimed on Wednesday that evidence from a late-stage trial of Eisai and Biogen's Alzheimer's disease medication suggests that patients received a significant benefit.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.

2.

Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness

3.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

4.

According to a study, taking part in a clinical trial for cancer may not actually increase survival.

5.

A new blood test greatly increases the ability to detect cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot